Akademik Veri Yönetim Sistemi
TÜRK KALP VE DAMAR CERRAHİSİ DERNEĞİ 17. KONGRESİ, Antalya, Türkiye, 17 Kasım 2022, cilt.30, ss.44
BACKGROUND AND AIM:The use of
endovenous cyanoacrylate ablation (CAA), which is one of the new techniques in
the treatment of symptomatic venous insufficiency, has become increasingly
common worldwide. We aimed to evaluate the 36-month efficacy and safety of CAA
for the treatment of refluxing great saphenous veins in comparison with
endovenous laser ablation (EVLA).
METHODS:In this prospective
randomized study, 400 patients with refluxing great saphenous veins were
assigned to either CAA or EVLA. In their third year follow-up, physical
examination and duplex ultrasound were performed; venous clinical severity
scores and quality of life questionnaires were evaluated by the investigators.
Overall success rates at 36 months were compared.
RESULTS:Of 400 randomized
subjects, 316 completed the 36-month follow-up, which were 159 in the CAA group
and 157 in the EVLA group. The complete closure rate was 93.8% in the CAA group
and 91.2% in the EVLA group based on month 36. The improvement in symptoms and
quality of life was the same in both groups and increased, though at a slower
pace. Device or procedure-related late side effects were not observed in either
group.
CONCLUSIONS:Based on 36 months
follow-up, this study showed that the efficacy and safety of CAA in the
menagement of refluxing great saphenous veins was similar to EVLA and
non-inferior to EVLA with high closure rate. The improvement in clinical and
quality of life results were continued in both treatment modalities and were
found to be similar.
Keywords: Endovenous
cyanoacrylate ablation